References
Chia SK, Speers CH, D’yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2007;110:973–9.
Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.
Greenberg PA, Hortobagyi GN, Smith TL, et al. Long term follow-up of patients with complete remission following chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14:2197–205.
Giordano SH, Buzdar AU, Smith TL, et al. Is breast cancer survival improving? Cancer. 2004;100:44–52.
Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109–19.
Conflict of interest
The author declares that there is no actual or potential conflict of interest in relation to this article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stöger, H. Breast cancer—advanced stage: “cure—still a long way to go?”. memo 5, 85–86 (2012). https://doi.org/10.1007/s12254-012-0022-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12254-012-0022-3